The Patent Finder
HL

Hoffmann-La Roche Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

884 patents currently held

80 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
91 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
91
Ending by 2030
Dec 2026
Next term end
640
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Bispecific T Cell Activating Antigen Binding Molecules US 9,914,776
Cited by 91 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Ends Sep 2035 · High confidence Also notable
Treatment Method US 11,013,801
Cited by 53 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2036.
Ends Dec 2036 · High confidence Also notable
Protease-Activated T Cell Bispecific Molecules US 11,242,390
Cited by 24 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2037.
Ends Mar 2037 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 21 fees due Dec 2 to 30, 2026 · next Dec 2
  • 13 fees due Jan 2 to 30, 2027 · next Jan 2
  • 21 fees due Feb 1 to 28, 2027 · next Feb 1
  • 8 fees due Mar 1 to 26, 2027 · next Mar 1
  • 20 fees due Apr 1 to 30, 2027 · next Apr 1
  • 10 fees due May 10 to 28, 2027 · next May 10
  • 16 fees due Jun 1 to 30, 2027 · next Jun 1
  • 9 fees due Jul 2 to 28, 2027 · next Jul 2
  • 15 fees due Aug 6 to 27, 2027 · next Aug 6
  • 14 fees due Sep 10 to 30, 2027 · next Sep 10
  • 20 fees due Oct 2 to 30, 2027 · next Oct 2
  • 8 fees due Nov 3 to 12, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 640 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Portion of a Display Screen with a Graphical User Interface (2020)13 in forceto Apr 2038
Portion of a Display Screen with a Graphical User Interface (2020)10 in forceto Dec 2037
Antibodies Against Human CSF-1R and Uses Thereof9 in forceto Dec 2032
Subcutaneously Administered ANTI-IL-6 Receptor Antibody for Treatment of Systemic Sclerosis6 in forceto Aug 2032
Anti-Alpha-Synuclein Antibodies and Methods of Use5 in forceto Nov 2034

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 9,272,031Antibodies Against Amyloid Beta 4 with Glycosylation in the Variable Region
In force
 · Medium confidence
In forceMedium confidence
US 7,582,789Ibandronate Polymorph
In force
 · High confidence
In forceHigh confidence
US 7,714,158Ibandronate Polymorph
In force
 · High confidence
In forceHigh confidence
US 7,425,551Malonamide Derivatives
In force
 · High confidence
In forceHigh confidence
US 7,514,426Substituted Imidazol[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine Derivatives
In force
 · Medium confidence
In forceMedium confidence
US 11,673,958Glycosylated Antibodies
In force
 · Low confidence
In forceLow confidence
US 7,504,544Asymmetric Hydrogenation of 1,1,1- Trifluoroacetone
In force
 · High confidence
In forceHigh confidence
US 7,642,264Phenyl-Substituted Pyrimidine Derivatives as MG1UR Antagonists
In force
 · High confidence
In forceHigh confidence
US 7,955,806Detection of a Therapeutic Antibody in an Experimental Animal
In force
 · High confidence
In forceHigh confidence
US 12,559,561Glycosylated Antibodies
In force
 · Medium confidence
In forceMedium confidence
10 of 884 patents shown.
Pro members see all 884.
Pro members: see all 884 patents
Also on record, not counted in the 884: 80 patents in force now held by others · 1,064 patents ended · 699 applications pending · 1,177 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Export every term end as CSV · Pro
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited